The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer

Authors:

Abstract
No abstract available
Funding Information
  • AbbVie
  • National Cancer Institute (CA-16359, P50CA196530, R01-CA126801)
  • Shire
  • Merck Company Foundation
  • Exelixis
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals North America
  • Spectrum Pharmaceuticals
  • Novartis
  • Sanofi
  • Johnson & Johnson Innovative Medicine
  • Yale Cancer Center
  • Eli Lilly and Company
  • Clovis Oncology
  • Pfizer
  • Yale SPORE in Lung Cancer

This publication has 47 references indexed in Scilit: